- Home
- DSM vs RXST Comparison
DSM vs RXST Comparison
Compare DSM & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | RXST |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 305.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DSM | RXST |
|---|---|---|
| Price | $6.09 | $7.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.78 |
| AVG Volume (30 Days) | 122.1K | ★ 730.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.39 | $5.90 |
| 52 Week High | $6.30 | $16.73 |
Technical Indicators
Market Signals| Indicator | DSM | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 54.82 |
| Support Level | $5.93 | $7.34 |
| Resistance Level | $6.24 | $9.11 |
| Average True Range (ATR) | 0.09 | 0.41 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 76.19 | 92.50 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.